Secondary analysis of 480 men in the ProtecT trial treated with radical prostatectomy: all 21 metastatic or lethal events occurred in the 143 with cribriform-positive cancer (15-year cumulative incidence 14%); none in cribriform-negative disease.
Secondary analysisn = 480
Sushentsev et al. Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial